423 related articles for article (PubMed ID: 9170522)
21. [Expression and clinical significance of nuclear matrix protein 22 and cytokeratin 18 in transitional cell carcinoma of the bladder].
Song JW; DU LL; Zhao XW; Jing JX; Han CZ; Cui Y; Liu JW; Hao HL; Wang ZG; Mi ZG
Zhonghua Zhong Liu Za Zhi; 2009 Apr; 31(4):274-7. PubMed ID: 19615282
[TBL] [Abstract][Full Text] [Related]
22. Comparative evaluation of the diagnostic performance of the BTA stat test, NMP22 and urinary bladder cancer antigen for primary and recurrent bladder tumors.
Giannopoulos A; Manousakas T; Gounari A; Constantinides C; Choremi-Papadopoulou H; Dimopoulos C
J Urol; 2001 Aug; 166(2):470-5. PubMed ID: 11458049
[TBL] [Abstract][Full Text] [Related]
23. A multigene urine test for the detection and stratification of bladder cancer in patients presenting with hematuria.
O'Sullivan P; Sharples K; Dalphin M; Davidson P; Gilling P; Cambridge L; Harvey J; Toro T; Giles N; Luxmanan C; Alves CF; Yoon HS; Hinder V; Masters J; Kennedy-Smith A; Beaven T; Guilford PJ
J Urol; 2012 Sep; 188(3):741-7. PubMed ID: 22818138
[TBL] [Abstract][Full Text] [Related]
24. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
25. Soluble Fas--a promising novel urinary marker for the detection of recurrent superficial bladder cancer.
Svatek RS; Herman MP; Lotan Y; Casella R; Hsieh JT; Sagalowsky AI; Shariat SF
Cancer; 2006 Apr; 106(8):1701-7. PubMed ID: 16541433
[TBL] [Abstract][Full Text] [Related]
26. Urinary level of nuclear matrix protein 22 in the diagnosis of bladder cancer: experience with 130 patients with biopsy confirmed tumor.
Casella R; Huber P; Blöchlinger A; Stoffel F; Dalquen P; Gasser TC; Lehmann K
J Urol; 2000 Dec; 164(6):1926-8. PubMed ID: 11061883
[TBL] [Abstract][Full Text] [Related]
27. Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer.
Shariat SF; Marberger MJ; Lotan Y; Sanchez-Carbayo M; Zippe C; Lüdecke G; Boman H; Sawczuk I; Friedrich MG; Casella R; Mian C; Eissa S; Akaza H; Serretta V; Huland H; Hedelin H; Raina R; Miyanaga N; Sagalowsky AI; Roehrborn CG; Karakiewicz PI
J Urol; 2006 Sep; 176(3):919-26; discussion 926. PubMed ID: 16890655
[TBL] [Abstract][Full Text] [Related]
28. Urinary nuclear matrix protein 22 as a new marker for the screening of urothelial cancer in patients with microscopic hematuria.
Miyanaga N; Akaza H; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Int J Urol; 1999 Apr; 6(4):173-7. PubMed ID: 10226833
[TBL] [Abstract][Full Text] [Related]
29. [The clinical efficacy of Bladder Chek NMP22 in urothelial cancer].
Yokoyama T; Sekigawa R; Hayashi T; Horita S; Kanamuro T; Nonami Y; Sawada T; Nishikawa T; Kobayashi M; Yamaguchi Y; Ishida H; Goya N; Nakazawa H; Toma H
Rinsho Byori; 2004 Mar; 52(3):199-203. PubMed ID: 15137316
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of nuclear matrix protein-22 as a clinical diagnostic marker for bladder cancer.
Chang YH; Wu CH; Lee YL; Huang PH; Kao YL; Shiau MY
Urology; 2004 Oct; 64(4):687-92. PubMed ID: 15491702
[TBL] [Abstract][Full Text] [Related]
31. Nuclear matrix protein-22: a prospective evaluation in a population at risk for bladder cancer. Results from the UroScreen study.
Huber S; Schwentner C; Taeger D; Pesch B; Nasterlack M; Leng G; Mayer T; Gawrych K; Bonberg N; Pelster M; Johnen G; Bontrup H; Wellhäusser H; Bierfreund HG; Wiens C; Bayer C; Eberle F; Scheuermann B; Kluckert M; Feil G; Brüning T; Stenzl A;
BJU Int; 2012 Sep; 110(5):699-708. PubMed ID: 22313585
[TBL] [Abstract][Full Text] [Related]
32. Urinary levels of tumor-associated trypsin inhibitor (TATI) in the detection of transitional cell carcinoma of the urinary bladder.
Shariat SF; Herman MP; Casella R; Lotan Y; Karam JA; Stenman UH
Eur Urol; 2005 Sep; 48(3):424-31. PubMed ID: 15963628
[TBL] [Abstract][Full Text] [Related]
33. Usefulness of NMP22 as an adjunct to a typical urine cytology and low-grade urothelial carcinoma.
Arora VK; Sarungbam J; Bhatia A; Singh N; Agrawal V; Aggarwal S
Diagn Cytopathol; 2010 Nov; 38(11):788-90. PubMed ID: 20014314
[TBL] [Abstract][Full Text] [Related]
34. The clinical usefulness of nuclear matrix protein-22 in patients with end-stage renal disease and microscopic hematuria.
Trojan B; Tang A; Chandrapal J; Filleur S; Nelius T
Ren Fail; 2013; 35(1):72-6. PubMed ID: 23151051
[TBL] [Abstract][Full Text] [Related]
35. Validation of the diagnostic value of NMP22 BladderChek test as a marker for bladder cancer by photodynamic diagnosis.
Tritschler S; Scharf S; Karl A; Tilki D; Knuechel R; Hartmann A; Stief CG; Zaak D
Eur Urol; 2007 Feb; 51(2):403-7; discussion 407-8. PubMed ID: 16939699
[TBL] [Abstract][Full Text] [Related]
36. Urinary insulin-like growth factor 2 identifies the presence of urothelial carcinoma of the bladder.
Watson JA; Burling K; Fitzpatrick P; Kay E; Kelly J; Fitzpatrick JM; Dervan PA; McCann A
BJU Int; 2009 Mar; 103(5):694-7. PubMed ID: 19040529
[TBL] [Abstract][Full Text] [Related]
37. Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection.
Lotan Y; Capitanio U; Shariat SF; Hutterer GC; Karakiewicz PI
BJU Int; 2009 May; 103(10):1368-74. PubMed ID: 19338566
[TBL] [Abstract][Full Text] [Related]
38. [Significance of urinary nuclear matrix protein 22 in diagnosis of transitional cell carcinoma of urinary tract].
Shao Y; Zhuang J; Xu SX; Liu DY
Ai Zheng; 2002 Sep; 21(9):1005-7. PubMed ID: 12508552
[TBL] [Abstract][Full Text] [Related]
39. Influence of urinary tract instrumentation and inflammation on the performance of urine markers for the detection of bladder cancer.
Todenhöfer T; Hennenlotter J; Kühs U; Tews V; Gakis G; Aufderklamm S; Stenzl A; Schwentner C
Urology; 2012 Mar; 79(3):620-4. PubMed ID: 22386412
[TBL] [Abstract][Full Text] [Related]
40. [The diagnosis and monitoring of transitional cell cancer of the urinary tract through nuclear matrix protein 22].
Chen HQ; Han CZ; Du LL; Cui Y; Pang DZ; Jing JX; Zhao XW; Tian BG; Mi ZG
Zhonghua Yu Fang Yi Xue Za Zhi; 2007 Jun; 41 Suppl():84-6. PubMed ID: 17767866
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]